About Us

Fibronostics is a digital healthcare company shaping the future of noninvasive diagnostics for metabolic disease by applying neural network artificial intelligence to blood-based biomarkers.Our first generation products focused on patient identification screening and prognosis of chronic liver disease such as NAFLD/MAFLD and NASH.

The company is incorporated in Delaware with a fully-owned subsidiary in Singapore. We are currently commercially active in North America, Asia, Europe and LATAM.​

Fibronsotics mission

Our Mission

To improve human health by bringing artificial intelligence-based solutions to the diagnosis of major metabolic diseases​.

Management Team

Roni Amiel Fibronostics CEO

Sven Henrichwark

Chief Executive Officer

Chief Financial Officer Fibronostics

Dr. Mona Munteanu

Chief Scientific Officer,PhD

Chief Medical Officer Fibronostics

Dr. Ronald Quiambao

Chief Medical Officer MD, PhD

Chief Financial Officer Fibronostics

Owen Parr

VP Sales

CTO

John Lee

CTO

Chief Financial Officer Fibronostics

Aida Jailani

Operations Director

Scientific Advisors

Clinical Associate Professor of Medicine Texas A&M University

Dr. Imtiaz Alam

Clinical Associate Professor of Medicine Texas A&M University


Medical Technology SPRIM VENTURES

Dr. Victor de Lédinghen

Head of the Hepatology & Liver Transplantation Unit, Bordeaux University Hospital


Dr. Scott Friedman

Dr. Scott Friedman

Professor of Medicine, Loma Linda University Loma Linda, CA


Dr. Meena Bansal

Dr. Meena Bansal

Professor of Medicine, Liver Disaeses Mount Sinai, New York


Dr. Naim Alkhouri

Dr. Naim Alkhouri

Professor of Medicine, Liver Disaeses Mount Sinai, New York


Noninvasive Diagnostic Technology